These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 14971639)

  • 1. Patients with obsessive-compulsive disorder (OCD) displayed cognitive deficits consistent with a dysfunction of the dorsolateral-striatal circuit.
    Fontenelle LF; Mendlowicz MV; Versiani M
    Psychol Med; 2004 Jan; 34(1):181; author reply 181-3. PubMed ID: 14971639
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuropsychological performance of OCD patients before and after treatment with fluoxetine: evidence for persistent cognitive deficits.
    Nielen MM; Den Boer JA
    Psychol Med; 2003 Jul; 33(5):917-25. PubMed ID: 12877406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with obsessive-compulsive disorder (OCD) displayed cognitive deficits consistent with a dysfunction of the dorsolateral-striatal circuit.
    Fontenelle LF; Mendlowicz MV; Versiani M
    Psychol Med; 2004 Oct; 34(7):1367-8; author reply 1368-9. PubMed ID: 15697063
    [No Abstract]   [Full Text] [Related]  

  • 4. The use of fluoxetine in Gilles de la Tourette syndrome and obsessive compulsive behaviours: preliminary clinical experience.
    Eapen V; Trimble MR; Robertson MM
    Prog Neuropsychopharmacol Biol Psychiatry; 1996 May; 20(4):737-43. PubMed ID: 8843495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ritanserin as adjunct to fluoxetine treatment of OCD patients with psychotic features.
    Bach M; Aigner M; Lenz G
    Pharmacopsychiatry; 1997 Jan; 30(1):28-9. PubMed ID: 9065968
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of Silybum marianum (L.) Gaertn. with fluoxetine in the treatment of Obsessive-Compulsive Disorder.
    Sayyah M; Boostani H; Pakseresht S; Malayeri A
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):362-5. PubMed ID: 20035818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropsychological predictors of response to randomized treatment in obsessive-compulsive disorder.
    D'Alcante CC; Diniz JB; Fossaluza V; Batistuzzo MC; Lopes AC; Shavitt RG; Deckersbach T; Malloy-Diniz L; Miguel EC; Hoexter MQ
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):310-7. PubMed ID: 22789662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of comorbid body dysmorphic disorder on the response to sequential pharmacological trials for obsessive-compulsive disorder.
    Diniz JB; Costa DL; Cassab RC; Pereira CA; Miguel EC; Shavitt RG
    J Psychopharmacol; 2014 Jun; 28(6):603-11. PubMed ID: 24288238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obsessive compulsive disorder and depression--first results of a prospective study on 74 patients.
    Demal U; Zitterl W; Lenz G; Zapotoczky HG; Zitterl-Eglseer K
    Prog Neuropsychopharmacol Biol Psychiatry; 1996 Jul; 20(5):801-13. PubMed ID: 8870065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An adolescent male with multiple paraphilias successfully treated with fluoxetine.
    Galli VB; Raute NJ; McConville BJ; McElroy SL
    J Child Adolesc Psychopharmacol; 1998; 8(3):195-7. PubMed ID: 9853694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder.
    Sayyah M; Boostani H; Pakseresht S; Malayeri A
    Psychiatry Res; 2011 Oct; 189(3):403-6. PubMed ID: 21329988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy assessment of fluoxetine treatment of outpatients with obsessive-compulsive disorder: a preliminary report].
    Wandzel L
    Psychiatr Pol; 1997; 31(4):429-35. PubMed ID: 9527686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The treatment of psychogenic excoriation and obsessive compulsive disorder using aripiprazole and fluoxetine.
    Curtis AR; Richards RW
    Ann Clin Psychiatry; 2007; 19(3):199-200. PubMed ID: 17729023
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of fluvoxamine and behavior therapy on children and adolescents with obsessive-compulsive disorder.
    Neziroglu F; Yaryura-Tobias JA; Walz J; McKay D
    J Child Adolesc Psychopharmacol; 2000; 10(4):295-306. PubMed ID: 11191690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoxetine in the treatment of obsessive compulsive disorder.
    Fontaine R; Chouinard G
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):605-8. PubMed ID: 3878975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose paroxetine treatment for an adolescent with obsessive-compulsive disorder comorbid with Asperger's disorder.
    Sasayama D; Sugiyama N; Imai J; Hayashida A; Harada Y; Amano N
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):251. PubMed ID: 19335398
    [No Abstract]   [Full Text] [Related]  

  • 17. Fluoxetine in the treatment of Huntington's disease.
    De Marchi N; Daniele F; Ragone MA
    Psychopharmacology (Berl); 2001 Jan; 153(2):264-6. PubMed ID: 11205429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder.
    Jenike MA; Baer L; Buttolph L
    J Clin Psychiatry; 1991 Jan; 52(1):13-4. PubMed ID: 1988411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prozac for pediatric use.
    FDA Consum; 2003; 37(2):3. PubMed ID: 12715749
    [No Abstract]   [Full Text] [Related]  

  • 20. Manic behaviors associated with fluoxetine in three 12- to 18-year-olds with obsessive-compulsive disorder.
    Go FS; Malley EE; Birmaher B; Rosenberg DR
    J Child Adolesc Psychopharmacol; 1998; 8(1):73-80. PubMed ID: 9639082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.